You are here

P&T News

May 2

First and only FDA-approved drug for Parkinson-associated hallucinations and delusions
Registry will provide long-term safety and effectiveness data
Possible link to long wait times for VA care
Allergan’s rosuvastatin calcium joins a $6.5 billion market
Subcutaneous nonopioid relieves pain with less toxicity and abuse potential

April 29

First authorized test from commercial lab in U.S.
Combo treatment with lenalidomide and dexamethasone extends progression-free survival
Topoisomerase 1 inhibitors may blunt inflammatory storms

April 28

Medicare EHR incentive system will be phased out
Guidance emphasizes individualized treatment

April 27

Hospitals, insurers, and businesses prod drug-makers
Product overcomes patent-infringement lawsuit

Pages